Complement regulation in renal disease models

Seminars in Nephrology

Volumn 33, Issue 6, 2013, Pages 575-585

  Naik, Abhijit ^a   Sharma, Shweta ^b   Quigg, Richard J ^c  

^a UNIVERSITY OF CHICAGO   (United States)

^b Trauma Research Department St Anthony Hospital   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

Complement; Factor H; Glomerulonephritis; Membranous nephropathy; Thrombotic microangiopathy

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A RECEPTOR; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT RECEPTOR; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT LECTIN PATHWAY; COMPLEMENT SYSTEM; DISEASE MODEL; FOCAL GLOMERULOSCLEROSIS; HEYMANN NEPHRITIS; HUMAN; IMMUNE COMPLEX NEPHRITIS; IMMUNOREGULATION; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SERUM SICKNESS; T LYMPHOCYTE ACTIVATION; THROMBOTIC THROMBOCYTOPENIC PURPURA;

COMPLEMENT; FACTOR H; GLOMERULONEPHRITIS; MEMBRANOUS NEPHROPATHY; THROMBOTIC MICROANGIOPATHY;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT FACTOR H; COMPLEMENT SYSTEM PROTEINS; DISEASE MODELS, ANIMAL; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; LUPUS NEPHRITIS; MICE; THROMBOTIC MICROANGIOPATHIES;

EID: 84886241417     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2013.08.008     Document Type: Article

References (107)

1. Niculescu F., Rus H. Mechanisms of signal transduction activated by sublytic assembly of terminal complement complexes on nucleated cells. Immunol Res 2001, 24:191-199.
2. Bohana-Kashtan O., Ziporen L., Donin N., et al. Cell signals transduced by complement. Mol Immunol 2004, 41:583-597.
3. Cybulsky A.V., Quigg R.J., Salant D.J. Experimental membranous nephropathy redux. Am J Physiol Renal Fluid Electrolyte Physiol 2005, 289:F660-F671.
4. Nonaka M., Kimura A. Genomic view of the evolution of the complement system. Immunogenetics 2006, 58:701-713.
5. Bradley D.T., Zipfel P.F., Hughes A.E. Complement in age-related macular degeneration: a focus on function. Eye (Lond) 2011, 25:683-693.
6. Oppermann M., Wurzner R. Modern determination of complement activation. Semin Thromb Hemost 2010, 36:611-619.
7. Heurich M., Martinez-Barricarte R., Francis N.J., et al. Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proc Natl Acad Sci U S A 2011, 108:8761-8766.
8. Harris C.L., Heurich M., Rodriguez de C.S., et al. The complotype: dictating risk for inflammation and infection. Trends Immunol 2012, 33:513-521.
9. Sim R.B., Twose T.M., Paterson D.S., et al. The covalent-binding reaction of complement component C3. Biochem J 1981, 193:115-127.
10. Podack E.R., Tschopp J. Membrane attack by complement. Mol Immunol 1984, 21:589-603.
11. Morgan B.P., Harris C.L. Regulation in the activation pathways. In: Complement regulatory proteins 1999, 41-136. Academic Press, San Diego.
12. Alper C.A., Rosen F.S., Lachmann P.J. Inactivator of the third component of complement as an inhibitor in the properdin pathway. Proc Natl Acad Sci U S A 1972, 69:2910-2913.
13. Roozendaal R., Carroll M.C. Complement receptors CD21 and CD35 in humoral immunity. Immunol Rev 2007, 219:157-166.
14. Lalli P.N., Strainic M.G., Yang M., et al. Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis. Blood 2008, 112:1759-1766.
15. Lalli P.N., Zhou W., Sacks S., et al. Locally produced and activated complement as a mediator of alloreactive T cells. Front Biosci (Schol Ed) 2009, 1:117-124.
16. Strainic M.G., Liu J., Huang D., et al. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity 2008, 28:425-435.
17. Weaver D.J., Reis E.S., Pandey M.K., et al. C5a receptor-deficient dendritic cells promote induction of Treg and Th17 cells. Eur J Immunol 2010, 40:710-721.
18. Sacks S. Complement fragments C3a and C5a: the salt and pepper of the immune response. Eur J Immunol 2010, 40:668-670.
19. Sacks S.H., Zhou W. Allograft rejection: effect of local synthesis of complement. Springer Semin Immunopathol 2005, 27:332-344.
20. Brown K.M., Kondeatis E., Vaughan R.W., et al. Influence of donor C3 allotype on late renal-transplantation outcome. N Engl J Med 2006, 354:2014-2023.
21. Barlow P.N., Baron M., Norman D.G., et al. Secondary structure of a complement control protein module by two-dimensional 1H NMR. Biochemistry 1991, 30:997-1004.
22. Barlow P.N., Norman D.G., Steinkasserer A., et al. Solution structure of the fifth repeat of factor H: a second example of the complement control protein module. Biochemistry 1992, 31:3626-3634.
23. Aslam M., Guthridge J.M., Hack B.K., et al. The extended multidomain solution structures of the complement protein Crry and its chimeric conjugate Crry-Ig by scattering, analytical ultracentrifugation and constrained modelling: implications for function and therapy. J Mol Biol 2003, 329:525-550.
24. Kristensen T., Wetsel R.A., Tack B.F. Structural analysis of human complement protein H: homology with C4b binding protein, beta 2-glycoprotein I, and the Ba fragment of B2. J Immunol 1986, 136:3407-3411.
25. Kristensen T., Tack B.F. Murine protein H is comprised of 20 repeating units, 61 amino acids in length. Proc Natl Acad Sci U S A 1986, 83:3963-3967.
26. Demberg T., Pollok-Kopp B., Gerke D., et al. Rat complement factor H: molecular cloning, sequencing and quantification with a newly established ELISA. Scand J Immunol 2002, 56:149-160.
27. Paul M.S., Aegerter M., O'Brien S.E., et al. The murine complement receptor gene family. I. Analysis of mCRY gene products and their homology to human CR1. J Immunol 1989, 142:582-589.
28. Molina H., Wong W., Kinoshita T., et al. Distinct receptor and regulatory properties of recombinant mouse complement receptor 1 (CR1) and Crry, the two genetic homologues of human CR1. J Exp Med 1992, 175:121-129.
29. Quigg R.J., Lo C.F., Alexander J.J., et al. Molecular characterization of rat Crry: widespread distribution of two alternative forms of Crry mRNA. Immunogenetics 1995, 42:362-367.
30. Harrison R.A., Lachmann P.J. The physiological breakdown of the third component of human complement. Mol Immunol 1980, 17:9-20.
31. Kim Y.-U., Kinoshita T., Molina H., et al. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein. J Exp Med 1995, 181:151-159.
32. Schwaeble W., Zwirner J., Schulz T.F., et al. Human complement factor H: expression of an additional truncated gene product of 43 kDa in human liver. Eur J Immunol 1987, 17:1485-1489.
33. Saland J.M., Emre S.H., Shneider B.L., et al. Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation. Am J Transplant 2006, 6:1948-1952.
34. Vaziri-Sani F., Holmberg L., Sjoholm A.G., et al. Phenotypic expression of factor H mutations in patients with atypical hemolytic uremic syndrome. Kidney Int 2006, 69:981-988.
35. Alexander J.J., Aneziokoro O.G.B., Chang A., et al. Distinct and separable roles of the complement system in factor H-deficient bone marrow chimeric mice with immune complex disease. J Am Soc Nephrol 2006, 17:1354-1361.
36. Endoh M., Yamashina M., Ohi H., et al. Immunohistochemical demonstration of membrane cofactor protein (MCP) of complement in normal and diseased kidney tissues. Clin Exp Immunol 1993, 94:182-188.
37. Ichida S., Yuzawa Y., Okada H., et al. Localization of the complement regulatory proteins in the normal human kidney. Kidney Int 1994, 46:89-96.
38. Cosio F.G., Sedmak D.D., Mahan J.D., et al. Localization of decay accelerating factor in normal and diseased kidneys. Kidney Int 1989, 36:100-107.
39. Quigg R.J., Nicholson-Weller A., Cybulsky A.V., et al. Decay accelerating factor regulates complement activation on glomerular epithelial cells. J Immunol 1989, 142:877-882.
40. Lin F., Fukuoka Y., Spicer A., et al. Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes. Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies. Immunology 2001, 104:215-225.
41. Bao L., Spiller O.B., JP, et al. Decay-accelerating factor expression in the rat kidney is restricted to the apical surface of podocytes. Kidney Int 2002, 62:2010-2021.
42. Inoue N., Ikawa M., Nakanishi T., et al. Disruption of mouse CD46 causes an accelerated spontaneous acrosome reaction in sperm. Mol Cell Biol 2003, 23:2614-2622.
43. Hebert L.A. The clearance of immune complexes from the circulation of man and other primates. Am J Kidney Dis 1991, 27:352-361.
44. Alexander J.J., Hack B.K., Cunningham P.N., et al. A protein with characteristics of factor H is present on rodent platelets and functions as the immune adherence receptor. J Biol Chem 2001, 276:32129-32135.
45. Ren G., Doshi M., Hack B.K., et al. Rat glomerular epithelial cells produce and bear factor H on their surface which is upregulated under complement attack. Kidney Int 2003, 64:914-922.
46. Alexander J.J., Wang Y., Chang A., et al. Mouse podocyte complement factor H - the functional analogue to human complement receptor 1. J Am Soc Nephrol 2007, 18:1157-1166.
47. Parker C. Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet 2009, 373:759-767.
48. Parker C.J. Paroxysmal nocturnal hemoglobinuria. Curr Opin Hematol 2012, 19:141-148.
49. Haines J.L., Hauser M.A., Schmidt S., et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005, 308:419-421.
50. Hageman G.S., Anderson D.H., Johnson L.V., et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A 2005, 102:7227-7232.
51. Edwards A.O., Ritter R., Abel K.J., et al. Complement factor H polymorphism and age-related macular degeneration. Science 2005, 308:421-424.
52. Pickering M.C., Cook H.T. Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals. Clin Exp Immunol 2008, 151:210-230.
53. Nath K.A., Hostetter M.K., Hostetter T.H. Pathophysiology of chronic tubulo-interstitial disease in rats. Interactions of dietary acid load, ammonia, and complement component C3. J Clin Invest 1985, 76:667-675.
54. Kraut J.A., Madias N.E. Consequences and therapy of the metabolic acidosis of chronic kidney disease. Pediatr Nephrol 2011, 26:19-28.
55. Funabashi K., Okada N., Matsuo S., et al. Tissue distribution of complement regulatory membrane proteins in rats. Immunology 1994, 81:444-451.
56. Thurman J.M., Lucia M.S., Ljubanovic D., et al. Acute tubular necrosis is characterized by activation of the alternative pathway of complement. Kidney Int 2005, 67:524-530.
57. Noris M., Caprioli J., Bresin E., et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010, 5:1844-1859.
58. Liszewski M.K., Leung M.K., Schraml B., et al. Modeling how CD46 deficiency predisposes to atypical hemolytic uremic syndrome. Mol Immunol 2007, 44:1570-1579.
59. Harris C.L., Pettigrew D.M., Lea S.M., et al. Decay-accelerating factor must bind both components of the complement alternative pathway C3 convertase to mediate efficient decay. J Immunol 2007, 178:352-359.
60. Salant D.J., Adler S., Darby C., et al. Influence of antigen distribution on the mediation of immunological glomerular injury. Kidney Int 1985, 27:938-950.
61. Jansen J.H., Hogåsen K., Mollnes T.E. Extensive complement activation in hereditary porcine membranoproliferative glomerulonephritis type II (porcine dense deposit disease). Am J Pathol 1993, 143:1356-1365.
62. Hogasen K., Jansen J.H., Mollnes T.E., et al. Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency. J Clin Invest 1995, 95:1054-1061.
63. Pickering M.C., Cook H.T., Warren J., et al. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet 2002, 31:424-428.
64. Ruseva M.M., Vernon K.A., Lesher A.M., et al. Loss of properdin exacerbates C3 glomerulopathy resulting from factor H deficiency. J Am Soc Nephrol 2013, 24:43-52.
65. Paixao-Cavalcante D., Hanson S., Botto M., et al. Factor H facilitates the clearance of GBM bound iC3b by controlling C3 activation in fluid phase. Mol Immunol 2009, 46:1942-1950.
66. Fakhouri F., de Jorge E.G., Brune F., et al. Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice. Kidney Int 2010, 79:279-286.
67. Rose K.L., Paixao-Cavalcante D., Fish J., et al. Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice. J Clin Invest 2008, 118:608-618.
68. Pickering M.C., Warren J., Rose K.L., et al. Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice. Proc Natl Acad Sci U S A 2006, 103:9649-9654.
69. Lesher A.M., Zhou L., Kimura Y., et al. Combination of factor H mutation and properdin deficiency causes severe C3 glomerulonephritis. J Am Soc Nephrol 2013, 24:53-65.
70. Stilmant M.M., Couser W.G., Cotran R.S. Experimental glomerulonephritis in the mouse associated with mesangial deposition of autologous ferritin immune complexes. Lab Invest 1975, 32:746-756.
71. Iskandar S.S., Gifford D.R. Emancipator SN. Immune complex acute necrotizing glomerulonephritis with progression to diffuse glomerulosclerosis. A murine model. Lab Invest 1988, 59:772-779.
72. Falk R.J., Jennette J.C. Immune complex induced glomerular lesions in C5 sufficient and deficient mice. Kidney Int 1986, 30:678-686.
73. Iskandar S.S., Jennette J.C., Wilkman A.S., et al. Interstrain variations in nephritogenicity of heterologous protein in mice. Lab Invest 1982, 46:344-351.
74. Quigg R.J., Lim A., Haas M., et al. Immune complex glomerulonephritis in C4- and C3-deficient mice. Kidney Int 1998, 53:320-330.
75. Li B., Sallee C., Dehoff M., et al. Mouse Crry/p65: characterization of monoclonal antibodies and the tissue distribution of a functional homologue of human MCP and DAF. J Immunol 1993, 151:4295-4305.
76. Nishikage H., Baranyi L., Okada H., et al. Role of a complement regulatory protein in rat mesangial glomerulonephritis. J Am Soc Nephrol 1995, 6:234-242.
77. Xu C., Mao D., Holers V.M., et al. A critical role for murine complement regulator Crry in fetomaternal tolerance. Science 2000, 287:498-501.
78. Bao L., Wang Y., Chen P., et al. Mesangial cell complement receptor 1-related protein y limits complement-dependent neutrophil accumulation in immune complex glomerulonephritis. Immunology 2009, 128:e895-e904.
79. Bao L., Haas M., Minto A.W., et al. Decay-accelerating factor but not CD59 limits experimental immune complex glomerulonephritis. Lab Invest 2007, 87:357-364.
80. Alexander J.J., Pickering M.C., Haas M., et al. Complement factor H limits immune complex deposition and prevents inflammation and scarring in glomeruli of mice with chronic serum sickness. J Am Soc Nephrol 2005, 16:52-57.
81. Alexander J.J., Chaves L., Chang A., et al. The C5a receptor has a key role in immune complex glomerulonephritis in complement factor H-deficient mice. Kidney Int 2012, 82:961-968.
82. Andrews B.S., Eisenberg R.A., Theofilopoulos A.N., et al. Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J Exp Med 1978, 148:1198-1215.
83. Hahn BH. Animal models of systemic lupus erythematosus. In: Wallace DJ, Hahn BH, editors. Dubois' lupus erythematosus. 6th ed. Baltimore, MD: Williams and Wilkins; 2001. p. 339-388.
84. Bao L., Haas M., Boackle S.A., et al. Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice. J Immunol 2002, 168:3601-3607.
85. Bao L., Haas M., Quigg R.J. Complement factor H deficiency accelerates development of lupus nephritis. J Am Soc Nephrol 2011, 22:285-295.
86. Noble B., Van Liew J.B., Andres G.A., et al. Factors influencing susceptibility of LEW rats to Heymann nephritis. Clin Immunol Immunopathol 1984, 30:241-254.
87. Salant D.J., Belok S., Madaio M.P., et al. A new role for complement in experimental membranous nephropathy in rats. J Clin Invest 1980, 66:1339-1350.
88. Quigg R.J., Holers V.M., Morgan B.P., et al. Crry and CD59 regulate complement in rat glomerular epithelial cells and are inhibited by the nephritogenic antibody of passive Heymann nephritis. J Immunol 1995, 154:3437-3443.
89. Cunningham P.N., Quigg R.J. Contrasting roles of complement activation and its regulation in membranous nephropathy. J Am Soc Nephrol 2005, 16:1214-1222.
90. Quigg R.J., Cybulsky A.V., Salant D.J. Effect of nephritogenic antibody on complement regulation in cultured rat glomerular epithelial cells. J Immunol 1991, 147:838-845.
91. Schiller B., He C., Salant D.J., et al. Inhibition of complement regulation is key to the pathogenesis of Heymann nephritis. J Exp Med 1998, 188:1353-1358.
92. Cunningham P.N., Hack B.K., Ren G., et al. Glomerular complement regulation is overwhelmed in passive Heymann nephritis. Kidney Int 2001, 60:900-909.
93. Ren G., Doshi M., Hack B.K., et al. Isolation and characterization of a novel rat factor H-related protein that is up-regulated in glomeruli under complement attack. J Biol Chem 2002, 277:48351-48358.
94. Bao L., Haas M. Pippin J, et al. Focal and segmental glomerulosclerosis induced in mice lacking decay-accelerating factor in T cells. J Clin Invest 2009, 119:1264-1274.
95. Nangaku M., Alpers C.E., Pippin J., et al. A new model of renal microvascular endothelial injury. Kidney Int 1997, 52:182-194.
96. Hughes J., Nangaku M., Alpers C.E., et al. C5b-9 membrane attack complex mediates endothelial cell apoptosis in experimental glomerulonephritis. Am J Physiol Renal Physiol 2000, 278:F747-F757.
97. Nangaku M., Alpers C.E., Pippin J., et al. CD59 protects glomerular endothelial cells from immune-mediated thrombotic microangiopathy in rats. J Am Soc Nephrol 1998, 9:590-597.
98. Mendrick D.L., Rennke H.G., Cotran R.S., et al. Monoclonal antibodies against rat glomerular antigens: production and specificity. Lab Invest 1983, 49:107-117.
99. Ren G., Hack B.K., Minto A.W., et al. A complement-dependent model of thrombotic thrombocytopenic purpura induced by antibodies reactive with endothelial cells. Clin Immunol 2002, 103:43-53.
100. Pickering M.C., de Jorge E.G., Martinez-Barricarte R., et al. Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med 2007, 204:1249-1256.
101. de Jorge E.G., Macor P., Paixao-Cavalcante D., et al. The development of atypical hemolytic uremic syndrome depends on complement C5. J Am Soc Nephrol 2011, 22:137-145.
102. Thurman J.M., Ljubanovic D., Edelstein C.L., et al. Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J Immunol 2003, 170:1517-1523.
103. Nomura A., Nishikawa K., Yuzawa Y., et al. Tubulointerstitial injury induced in rats by a monoclonal antibody which inhibits function of a membrane inhibitor of complement. J Clin Invest 1995, 96:2348-2356.
104. Thurman J.M., Royer P.A., Ljubanovic D., et al. Treatment with an inhibitory monoclonal antibody to mouse factor B protects mice from induction of apoptosis and renal ischemia/reperfusion injury. J Am Soc Nephrol 2006, 17:707-715.
105. Thurman J.M., Ljubanovic D., Royer P.A., et al. Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia/reperfusion. J Clin Invest 2006, 116:357-368.
106. Bao L., Wang Y., Chang A., et al. Unrestricted C3 activation occurs in Crry-deficient kidneys which rapidly leads to chronic renal failure. J Am Soc Nephrol 2007, 18:811-822.
107. Bao L., Wang Y., Haas M., et al. Distinct roles for C3a and C5a in complement-induced tubulointerstitial injury. Kidney Int 2011, 80:524-534.